Paclitaxel poliglumex. Cell Therapeutics/Chugai Pharmaceutical.
Cell Therapeutics Inc, under license from the MD Anderson Cancer Center and in collaboration with Chugai Pharmaceutical Co Ltd (the Japanese subsidiary of Roche), is developing paclitaxel poliglumex, an intravenous poly-(alpha-L-glutamic acid) conjugate of paclitaxel for the potential treatment of solid tumors.
Man
Martha
M
University of California San Francisco Comprehensive Cancer Center, 2nd Floor BCC, 1600 Divisidero Street, San Francisco, CA 94115, USA. mman@itsa.ucsf.edu
Rugo
Hope
H
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy*; D017239:Paclitaxel / Q000031:analogs & derivatives; D011099:Polyglutamic Acid / Q000009:adverse effects / Q000138:chemical synthesis / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use / Q000031:analogs & derivatives; D013329:Structure-Activity Relationship; D043823:Taxoids / Q000009:adverse effects / Q000138:chemical synthesis / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D043823:Taxoids; D011099:Polyglutamic Acid; D017239:Paclitaxel; C509139:paclitaxel poliglumex